Abstract
Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.
MeSH terms
-
Anticoagulants / adverse effects
-
Anticoagulants / therapeutic use*
-
Betacoronavirus / pathogenicity*
-
Blood Coagulation / drug effects*
-
COVID-19
-
COVID-19 Drug Treatment
-
Clinical Decision-Making
-
Coronavirus Infections / blood
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy*
-
Coronavirus Infections / virology
-
Hemorrhage / chemically induced
-
Host-Pathogen Interactions
-
Humans
-
Pandemics
-
Patient Selection
-
Pneumonia, Viral / blood
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy*
-
Pneumonia, Viral / virology
-
Risk Assessment
-
Risk Factors
-
SARS-CoV-2
-
Thromboembolism / blood
-
Thromboembolism / diagnosis
-
Thromboembolism / prevention & control*
-
Thromboembolism / virology
-
Treatment Outcome